Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
Phase 1
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo Solution
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06429930
- Locations
- 🇳🇿
NZCR Ltd (New Zealand Clinical Research), Christchurch, New Zealand
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: L608 Inhalation SolutionDrug: Placebo solution
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05938946
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ugDevice: L606 Inhalation SystemOther: Placebo Solution
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pharmosa Biopharm Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04041648
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
News
No news found